Role of microbiota, host genetics and mesenteric adipose in Crohn's disease fibrosis and post-op recurrence.
微生物群、宿主遗传学和肠系膜脂肪在克罗恩病纤维化和术后复发中的作用。
基本信息
- 批准号:10321575
- 负责人:
- 金额:$ 38.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-20 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adipose tissueAttenuatedAutomobile DrivingBacteriaBacterial TranslocationBiologicalBiologyBiopsyBloodCellsChronicClassificationCoculture TechniquesCollagenCollectionComplexComplicationCrohn&aposs diseaseDataDepositionDevelopmentDiseaseEnvironmentExcisionFaceFaminesFatty acid glycerol estersFecesFibroblastsFibrosisFingersFutureGenesGeneticGenetic Predisposition to DiseaseGenotypeGerm-FreeGoalsHyperplasiaImmuneImmune responseImmunologicsIndividualInflammationInterventionIntestinal FibrosisIntestinesLeftMediatingMesenteryMetagenomicsModelingMucous MembraneMusMyelogenousNewly DiagnosedOperative Surgical ProceduresOrganismPatient CarePatientsPatternPenetrancePharmaceutical PreparationsPhenotypePhysiological ProcessesPlayPliabilityPopulationPostoperative PeriodPrevalenceProcessPublic HealthRecurrenceRecurrent diseaseRepeat SurgeryResearchRiskRoleSeveritiesSiteSmall IntestinesTestingTherapeuticTherapeutic InterventionTimeTissuesTransgenic Micebasecell typeclinically relevantfungusgut inflammationgut microbiotahigh riskileumimmune activationinnovationinsightmacrophagemetabolomemetabolomicsmicrobialmicrobiomemicrobiome researchmicrobiotamicrobiota profilesmicroorganismnovel therapeuticspatient subsetspolygenic risk scorepreventprogramsresponsescreeningsingle-cell RNA sequencingtargeted treatment
项目摘要
Ileal fibrosis in Crohn’s Disease (CD) represents a complication in over 30% of CD patients, and leads to surgery
in nearly 75% of this population. While therapies exist to manage CD-related inflammation, no approved
medication exists to prevent or manage fibrosis, with surgery left as the only option. Despite surgical removal of
fibrotic strictures, they often recur, requiring repeated surgeries. Strategies to predict who is more likely to
develop these complications, and identification of targets for therapeutic intervention is needed. Our long-term
goal is to develop a screening process for CD patients that incorporates a patient’s polygenic risk score, gut
microbiota profile, and metabolome to identify individuals at high risk for developing fibrotic disease (for newly
diagnosed patients) and propensity for disease recurrence (in individuals who have undergone surgery for
removal of strictures). In parallel, we hope to identify key microbiota strongly associated with fibrosis and define
their mechanism of action, so that microbially-directed therapy may become a viable therapeutic option for these
patients. Our objective in this proposal is to define the relationship between polygenic risk, the microbiome, and
the intestinal and peri-intestinal environment contributing to the fibrotic sub-phenotype in ileal CD. The central
hypothesis of this proposal is that CD patients who develop fibrotic disease and recurrent strictures represent a
sub-phenotype characterized by a hyper-reactivity of ileal immune cells, and fibroblasts in surrounding
mesenteric fat, to certain microbiota. We hypothesize that immune reactivity to these microbiota in both the ileum
and mesenteric fat may be determined by an individual’s polygenic risk score. Our rationale is that the
identification of mechanisms to predict development of fibrosis will offer new therapeutic opportunities. Our
specific aims will test the following hypotheses: (Aim 1) genetic susceptibility to ileal fibrosis is mediated by an
excessive immune response to creeping fat (CrF) microorganisms; (Aim 2) ileal fibroblasts express collagen
matrix genes in the context of inflammation, is microbially-driven, and is related to propensity for recurrent
strictures; and (Aim 3) microorganisms associated with CrF will increase penetrance, severity, and/or shorten
time to disease in a model of spontaneous fibrosis. This contribution is significant because it will add new aspects
to our understanding of CD fibrosis by studying the microbiome, mesenteric fat, and polygenic risk scores to help
define this complicated phenotype. These insights have the potential to offer new targets and points of
intervention before complications occur. This option currently does not exist. Furthermore, this study will provide
the most comprehensive characterization to-date of creeping fat and help answer the mystery of why this
phenomenon occurs. This contribution is innovative because no studies to-date have investigated ileal CD
fibrosis taking into account the contribution of creeping fat to the fibrotic milieu. Insight into the peri-intestinal
environment, combined with microbial targets, and an individual’s genotype represents a combination of
analyses that is both new, clinically relevant, and ultimately, translatable into future patient care.
克罗恩病(CD)的回肠纤维化是超过30%的CD患者的并发症,并导致手术
在近75%的人口中虽然存在治疗CD相关炎症的疗法,但尚未批准
存在预防或管理纤维化的药物,手术是唯一的选择。尽管手术切除了
纤维化狭窄,他们经常复发,需要反复手术。预测谁更有可能
发展这些并发症,并确定治疗干预的目标是必要的。我们的长期
我们的目标是为CD患者开发一种筛查方法,该方法将患者的多基因风险评分、肠道
微生物群谱和代谢组,以识别患有纤维化疾病的高风险个体(对于新的
诊断的患者)和疾病复发倾向(在已经接受手术的个体中,
去除狭窄)。同时,我们希望确定与纤维化密切相关的关键微生物群,并定义
它们的作用机制,因此微生物导向疗法可能成为这些疾病的可行治疗选择。
患者我们在这项提案中的目标是确定多基因风险、微生物组和
肠和肠周环境导致回肠CD中的纤维化亚表型。中央
这一建议的假设是,发生纤维化疾病和复发性狭窄的CD患者代表了一种
亚表型特征为回肠免疫细胞和周围成纤维细胞的高反应性
肠系膜脂肪和某些微生物群。我们假设回肠和回肠中对这些微生物群的免疫反应性
和肠系膜脂肪可以通过个体的多基因风险评分来确定。我们的理由是,
鉴定预测纤维化发展的机制将提供新的治疗机会。我们
具体的目的将测试以下假设:(目的1)回肠纤维化的遗传易感性是由
对爬行脂肪(CrF)微生物的过度免疫反应;(目的2)回肠成纤维细胞表达胶原蛋白
基质基因在炎症的背景下,是微生物驱动的,并与复发的倾向,
狭窄;和(目的3)与CrF相关的微生物将增加狭窄率,严重程度和/或缩短
自发性纤维化模型中的发病时间。这一贡献意义重大,因为它将增加新的方面
通过研究微生物组、肠系膜脂肪和多基因风险评分来帮助我们了解CD纤维化,
来定义这个复杂的表型这些见解有可能提供新的目标和点,
在并发症发生之前进行干预。此选项当前不存在。此外,这项研究将提供
最全面的表征爬行脂肪的日期,并帮助回答为什么这个谜,
现象发生。这一贡献是创新的,因为迄今为止还没有研究调查回肠CD
考虑到蠕动脂肪对纤维化环境的贡献,纤维化。了解肠道周围
环境,结合微生物目标,和一个人的基因型代表了组合,
分析,这是新的,临床相关的,并最终转化为未来的病人护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Suzanne Devkota其他文献
Suzanne Devkota的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Suzanne Devkota', 18)}}的其他基金
Is Obesity an Infectious Disease?: Gut bacterial and fungal translocation as an underappreciated driver of visceral adipose expansion.
肥胖是一种传染病吗?:肠道细菌和真菌易位是内脏脂肪扩张的一个未被充分认识的驱动因素。
- 批准号:
10326683 - 财政年份:2021
- 资助金额:
$ 38.25万 - 项目类别:
Is Obesity an Infectious Disease?: Gut bacterial and fungal translocation as an underappreciated driver of visceral adipose expansion.
肥胖是一种传染病吗?:肠道细菌和真菌易位是内脏脂肪扩张的一个未被充分认识的驱动因素。
- 批准号:
10634683 - 财政年份:2021
- 资助金额:
$ 38.25万 - 项目类别:
Role of microbiota, host genetics and mesenteric adipose in Crohn's disease fibrosis and post-op recurrence.
微生物群、宿主遗传学和肠系膜脂肪在克罗恩病纤维化和术后复发中的作用。
- 批准号:
10549289 - 财政年份:2020
- 资助金额:
$ 38.25万 - 项目类别:
Microbial and metabolomic profiling of the intestinal microenvironment distinguishing patients with mild and severe COVID-19 symptoms.
肠道微环境的微生物和代谢组学分析可区分轻度和重度 COVID-19 症状的患者。
- 批准号:
10177673 - 财政年份:2020
- 资助金额:
$ 38.25万 - 项目类别:
Effect of W-3 supplementation on IBD via alterations in the enteric microbiome
补充 W-3 通过改变肠道微生物组对 IBD 产生影响
- 批准号:
7912766 - 财政年份:2010
- 资助金额:
$ 38.25万 - 项目类别:
Effect of W-3 supplementation on IBD via alterations in the enteric microbiome
补充 W-3 通过改变肠道微生物组对 IBD 产生影响
- 批准号:
8074567 - 财政年份:2010
- 资助金额:
$ 38.25万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 38.25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 38.25万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 38.25万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 38.25万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 38.25万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 38.25万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 38.25万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 38.25万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 38.25万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 38.25万 - 项目类别:
Idea to Innovation